Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A Phase II Trial of the Pan-HER Inhibitor Poziotinib, in Patients With HER2-Positive Metastatic Breast Cancer Who Had Received at Least Two Prior HER2-Directed Regimens: Results of the NOV120101-203 TrialInt. J. Cancer 2018 Jul 06;[EPub Ahead of Print], YH Park, KH Lee, JH Sohn, KS Lee, KH Jung, JH Kim, KH Lee, JS Ahn, TY Kim, GM Kim, IH Park, SB Kim, SH Kim, HS Han, YH Im, JH Ahn, JY Kim, J Kang, SA Im
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.